GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viva Biotech Holdings (HKSE:01873) » Definitions » Price-to-Free-Cash-Flow

Viva Biotech Holdings (HKSE:01873) Price-to-Free-Cash-Flow : 5.49 (As of Jun. 06, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Viva Biotech Holdings Price-to-Free-Cash-Flow?

As of today (2024-06-06), Viva Biotech Holdings's share price is HK$0.62. Viva Biotech Holdings's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.11. Hence, Viva Biotech Holdings's Price-to-Free-Cash-Flow Ratio for today is 5.49.

The historical rank and industry rank for Viva Biotech Holdings's Price-to-Free-Cash-Flow or its related term are showing as below:

HKSE:01873' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 3.95   Med: 16.63   Max: 25
Current: 5.49

During the past 8 years, Viva Biotech Holdings's highest Price-to-Free-Cash-Flow Ratio was 25.00. The lowest was 3.95. And the median was 16.63.

HKSE:01873's Price-to-Free-Cash-Flow is ranked better than
92.59% of 216 companies
in the Biotechnology industry
Industry Median: 30.425 vs HKSE:01873: 5.49

Viva Biotech Holdings's Free Cash Flow per Share for the six months ended in Dec. 2023 was HK$-0.01. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was HK$0.11.

During the past 12 months, the average Free Cash Flow per Share Growth Rate of Viva Biotech Holdings was 31.30% per year.

During the past 8 years, Viva Biotech Holdings's highest 3-Year average Free Cash Flow per Share Growth Rate was -127.00% per year. The lowest was -127.00% per year. And the median was -127.00% per year.


Viva Biotech Holdings Price-to-Free-Cash-Flow Historical Data

The historical data trend for Viva Biotech Holdings's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viva Biotech Holdings Price-to-Free-Cash-Flow Chart

Viva Biotech Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial - - - 21.88 10.00

Viva Biotech Holdings Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 21.88 - 10.00

Competitive Comparison of Viva Biotech Holdings's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Viva Biotech Holdings's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Viva Biotech Holdings's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viva Biotech Holdings's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Viva Biotech Holdings's Price-to-Free-Cash-Flow falls into.



Viva Biotech Holdings Price-to-Free-Cash-Flow Calculation

Viva Biotech Holdings's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=0.62/0.113
=5.49

Viva Biotech Holdings's Share Price of today is HK$0.62.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Viva Biotech Holdings's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.11.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Viva Biotech Holdings  (HKSE:01873) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Viva Biotech Holdings Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Viva Biotech Holdings's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Viva Biotech Holdings (HKSE:01873) Business Description

Traded in Other Exchanges
Address
735 Ziping Road, Pudong New District, Zhoupu Town, Shanghai, CHN, 201318
Viva Biotech Holdings is an integrated drug discovery platform. The company's operating segment includes Drug discovery services and Contract Development Manufacture Organisation (CDMO) and commercialisation services. It generates maximum revenue from the Contract Development Manufacture Organisation (CDMO) and commercialisation services segment. The Contract Development Manufacture Organisation ("CDMO") and commercialisation services segment includes contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates and formulations.
Executives
Mao Chen Cheney 2101 Beneficial owner
Wu John Jiong 2201 Interest of corporation controlled by you
Fenghe Harvest Ltd 2101 Beneficial owner
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Mao Jun 2501 Other
Temasek Holdings (private) Limited 2201 Interest of corporation controlled by you
Zhou Min 2202 Interest of your spouse
Intertrust (singapore) Ltd. 2301 Trustee
Z&m International Holdings Limited 2201 Interest of corporation controlled by you
Zhang And Sons Limited 2101 Beneficial owner

Viva Biotech Holdings (HKSE:01873) Headlines

No Headlines